Assessing eligibility for treatment in acute myeloid leukemia in 2023.

Acute myeloid leukemia Italy comorbidities elderly fitness geriatric scores intensive chemotherapy performance status

Journal

Expert review of hematology
ISSN: 1747-4094
Titre abrégé: Expert Rev Hematol
Pays: England
ID NLM: 101485942

Informations de publication

Date de publication:
03 2023
Historique:
medline: 31 3 2023
pubmed: 7 3 2023
entrez: 6 3 2023
Statut: ppublish

Résumé

Age has historically been considered the main criterion to determine eligibility for intensive chemotherapy in patients with acute myeloid leukemia (AML), but age alone can no longer be considered an absolute indicator in determining which patients should be defined as unfit. Assessment of fitness for a given treatment today serves an important role in tailoring therapeutic options. This review examines the main options used in real life to define eligibility for intensive and nonintensive chemotherapy in patients with AML, with a main focus on the Italian SIE/SIES/GITMO Consensus Criteria. Other published real-life experiences are also reviewed, analyzing the correlation between these criteria and short-term mortality, and thus expected outcomes. Assessment of fitness is mandatory at diagnosis to tailor treatment to the greatest degree possible, evaluating the patient's individual profile. This is especially relevant when considering the availability of newer, less toxic therapeutic regimens, which have shown promising results in patients with AML who are older or considered unfit for intensive treatment. Fitness assessment is now a fundamental part of AML management and a critical step that can potentially influence outcomes and not just predict them. In patients with acute myeloid leukemia (AML), age has generally been considered as the main factor to determine if intensive chemotherapy can be carried out (fitness). However, this has been gradually changing in recent years. In addition to age, comorbidities and overall performance status are also important in determining if the patient should undergo intensive chemotherapy and have an important role in tailoring therapeutic options. Consensus criteria to define eligibility for intensive and nonintensive chemotherapy in patients with AML have been proposed, which have been shown to correlate well with expected outcomes. Today, given the evolution of the treatment armamentarium, assessment of a patient’s ‘fitness’ is compulsory to select the most appropriate treatment for each patient.

Autres résumés

Type: plain-language-summary (eng)
In patients with acute myeloid leukemia (AML), age has generally been considered as the main factor to determine if intensive chemotherapy can be carried out (fitness). However, this has been gradually changing in recent years. In addition to age, comorbidities and overall performance status are also important in determining if the patient should undergo intensive chemotherapy and have an important role in tailoring therapeutic options. Consensus criteria to define eligibility for intensive and nonintensive chemotherapy in patients with AML have been proposed, which have been shown to correlate well with expected outcomes. Today, given the evolution of the treatment armamentarium, assessment of a patient’s ‘fitness’ is compulsory to select the most appropriate treatment for each patient.

Identifiants

pubmed: 36876439
doi: 10.1080/17474086.2023.2185603
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

181-190

Auteurs

Adriano Venditti (A)

Ematologia, Dipartimento di Biomedicina e Prevenzione, Università di Roma "Tor Vergata", Rome, Italy.

Roberto Cairoli (R)

Dipartimento Ematologia, Oncologia e Medicina Molecolare, ASST Grande Ospedale Metropolitano Niguarda-Milano, Milan, Italy.

Morena Caira (M)

Medical Department, AbbVie srl, Campoverde di Aprilia, Latina, Italy.

Paola Finsinger (P)

Medical Department, AbbVie srl, Campoverde di Aprilia, Latina, Italy.

Fabio Finocchiaro (F)

Medical Department, AbbVie srl, Campoverde di Aprilia, Latina, Italy.

Benedetta Neri (B)

Medical Department, AbbVie srl, Campoverde di Aprilia, Latina, Italy.

Daniela De Benedittis (D)

Medical Department, AbbVie srl, Campoverde di Aprilia, Latina, Italy.

Giuseppe Rossi (G)

Ematologia, ASST degli Spedali Civili, Brescia, Italy.

Felicetto Ferrara (F)

Divisione di Ematologia, Ospedale Antonio Cardarelli, Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH